Wall Street brokerages expect Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) to report earnings per share of ($0.65) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for Aquinox Pharmaceuticals’ earnings. Aquinox Pharmaceuticals reported earnings per share of ($0.48) in the same quarter last year, which would indicate a negative year over year growth rate of 35.4%. The business is expected to issue its next quarterly earnings report on Thursday, March 8th.

According to Zacks, analysts expect that Aquinox Pharmaceuticals will report full-year earnings of ($2.08) per share for the current year, with EPS estimates ranging from ($2.09) to ($2.06). For the next financial year, analysts anticipate that the company will report earnings of ($2.31) per share, with EPS estimates ranging from ($2.50) to ($2.11). Zacks’ EPS calculations are an average based on a survey of research analysts that follow Aquinox Pharmaceuticals.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last posted its earnings results on Wednesday, November 8th. The company reported ($0.50) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.62) by $0.12.

AQXP has been the topic of several analyst reports. Canaccord Genuity set a $22.00 target price on shares of Aquinox Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, December 11th. Zacks Investment Research lowered shares of Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. Needham & Company LLC reaffirmed a “buy” rating and issued a $25.00 target price on shares of Aquinox Pharmaceuticals in a report on Thursday, November 9th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and issued a $28.00 target price on shares of Aquinox Pharmaceuticals in a report on Thursday, November 9th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. Aquinox Pharmaceuticals has an average rating of “Hold” and a consensus target price of $22.00.

A number of large investors have recently modified their holdings of AQXP. Investment Centers of America Inc. bought a new stake in Aquinox Pharmaceuticals during the 3rd quarter worth about $175,000. Citadel Advisors LLC bought a new stake in Aquinox Pharmaceuticals during the 3rd quarter worth about $194,000. Bank of New York Mellon Corp grew its holdings in Aquinox Pharmaceuticals by 16.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 23,260 shares of the company’s stock worth $327,000 after acquiring an additional 3,299 shares during the last quarter. Sphera Funds Management LTD. grew its holdings in Aquinox Pharmaceuticals by 21.7% during the 3rd quarter. Sphera Funds Management LTD. now owns 75,535 shares of the company’s stock worth $1,072,000 after acquiring an additional 13,450 shares during the last quarter. Finally, Northern Trust Corp grew its holdings in Aquinox Pharmaceuticals by 3.3% during the 2nd quarter. Northern Trust Corp now owns 83,207 shares of the company’s stock worth $1,171,000 after acquiring an additional 2,691 shares during the last quarter. 96.26% of the stock is currently owned by hedge funds and other institutional investors.

Aquinox Pharmaceuticals (NASDAQ AQXP) traded up $0.35 on Friday, hitting $13.38. 250,421 shares of the stock traded hands, compared to its average volume of 96,384. Aquinox Pharmaceuticals has a fifty-two week low of $10.02 and a fifty-two week high of $19.97. The company has a market cap of $303.40 and a price-to-earnings ratio of -6.93.

ILLEGAL ACTIVITY WARNING: “” was published by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://www.com-unik.info/2018/02/02/1084108.html.

About Aquinox Pharmaceuticals

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.

Get a free copy of the Zacks research report on Aquinox Pharmaceuticals (AQXP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aquinox Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit